Literature DB >> 9152767

Myocardial blood flow and metabolism in patients with hypertrophic cardiomyopathy--a study with carbon-11 acetate and positron emission tomography.

S Ishiwata1, H Maruno, M Senda, H Toyama, S Nishiyama, A Seki.   

Abstract

The underlying pathophysiology of hypertrophic cardiomyopathy (HCM) is still unclear. positron emission tomography is a suitable and promising technique for the detection of possible metabolic consequences of the disease. To assess regional myocardial blood flow and metabolism, 19 asymptomatic or only mildly symptomatic patients with HCM and 10 normal control subjects were studied using carbon-11 acetate and fluorine-18-labelled deoxyglucose (FDG) as tracers of myocardial blood flow (Ao), oxygen consumption (k), and exogenous glucose utilization. In the patients, regional Ao in the hypertrophied septum and apex (H) was similar to that in the nonhypertrophied free wall (N) (91.3 +/- 3.9% vs 92.9 +/- 3.1%; p = NS). However, the k values were significantly lower in H than in N (0.044 +/- 0.012 vs 0.060 +/- 0.016/min, p < 0.0001). The k value in N and normal control subjects (0.062 +/- 0.013) was similar. Postprandial FDG uptake was lower in H than in N (70 +/- 16 vs 91 +/- 7%; p < 0.0001) in 16 patients and slightly higher in 3 patients. Fasting FDG study showed increased FDG uptake in H in 3 out of 13 patients, suggesting a disorder of the myocardial microvascular circulation. A relative decrease in hypertrophied septal and apical oxidative metabolism and glucose utilization without any corresponding perfusion defect could reflect abnormal regional aerobic metabolism in the disproportionately thickened myocardium in patients with HCM. This suggests that a primary myocardial metabolic defect might be present in patients with HCM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152767     DOI: 10.1253/jcj.61.201

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  3 in total

1.  BMIPP compared with PET metabolism.

Authors:  E Tadamura; N Tamaki; T Kudoh; N Hattori; J Konishi
Journal:  Int J Card Imaging       Date:  1999-02

2.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

3.  Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study.

Authors:  Helena Tuunanen; Johanna Kuusisto; Jyri Toikka; Pertti Jääskeläinen; Päivi Marjamäki; Keijo Peuhkurinen; Tapio Viljanen; Petri Sipola; Kira Q Stolen; Jarna Hannukainen; Pirjo Nuutila; Markku Laakso; Juhani Knuuti
Journal:  J Nucl Cardiol       Date:  2007-05-10       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.